Overview
Pharmacokinetics and Safety of BI 201335 in Patients With Mild to Severe Renal Impairment
Status:
Completed
Completed
Trial end date:
2012-06-01
2012-06-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The main objective of this study is to investigate the influence of mild, moderate and severe renal impairment on the pharmacokinetics and safety of BI 201335 in comparison to a control group with normal renal function after single dose of BI 201335.Phase:
Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Boehringer Ingelheim
Criteria
Inclusion criteria:Male and female healthy subjects with normal renal function and subjects with impaired
renal function in relatively good health
Exclusion criteria:
Any relevant deviation from healthy conditions for healthy volunteers or significant
diseases other than renal impairment for the renal impaired subjects